TEM

Tempus AI, Inc. Class A Common Stock

75.90 USD
-4.62
5.74%
At close Aug 25, 4:00 PM EDT
Pre-market
76.08
+0.18
0.24%
1 day
-5.74%
5 days
-2.94%
1 month
17.69%
3 months
15.23%
6 months
28.43%
Year to date
121.61%
1 year
25.43%
5 years
88.57%
10 years
88.57%
 

About: Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.

Employees: 2,400

0
Funds holding %
of 7,429 funds
0
Analysts bullish %
of 4 analysts

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

180% more first-time investments, than exits

New positions opened: 129 | Existing positions closed: 46

122% more call options, than puts

Call options by funds: $894M | Put options by funds: $403M

82% more capital invested

Capital invested by funds: $2.85B [Q1] → $5.2B (+$2.35B) [Q2]

65% more repeat investments, than reductions

Existing positions increased: 117 | Existing positions reduced: 71

26% more funds holding

Funds holding: 284 [Q1] → 359 (+75) [Q2]

13.36% more ownership

Funds ownership: 35.35% [Q1] → 48.71% (+13.36%) [Q2]

67% less funds holding in top 10

Funds holding in top 10: 15 [Q1] → 5 (-10) [Q2]

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$68
10%
downside
Avg. target
$75
2%
downside
High target
$85
12%
upside

4 analyst ratings

positive
75%
neutral
25%
negative
0%
BTIG
Mark Massaro
12%upside
$85
Buy
Maintained
20 Aug 2025
Morgan Stanley
Tejas Savant
10%downside
$68
Overweight
Maintained
12 Aug 2025
Guggenheim
Subbu Nambi
1%downside
$75
Buy
Maintained
30 Jun 2025
B of A Securities
Michael Ryskin
8%downside
$70
Neutral
Maintained
25 Jun 2025

Financial journalist opinion

Based on 79 articles about TEM published over the past 30 days

Positive
Zacks Investment Research
16 hours ago
Tempus AI or Butterfly: Which AI Health Tech Stock is a Buy Now?
BFLY trades at distressed levels with analyst targets signaling sharp upside, while TEM's premium valuation tempers its appeal.
Tempus AI or Butterfly: Which AI Health Tech Stock is a Buy Now?
Neutral
The Motley Fool
3 days ago
The Next Big Thing: 2 AI-Powered Healthcare Stocks Ready to Explode
It's certainly no secret that artificial intelligence (AI) has the potential to change, well, everything for most industries. It's already reshaped several sectors, in fact, and promises to reshape even more in the foreseeable future.
The Next Big Thing: 2 AI-Powered Healthcare Stocks Ready to Explode
Neutral
Business Wire
3 days ago
Tempus Announces the Acquisition of Paige
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the acquisition of Paige, an AI company specializing in digital pathology. The acquisition allows Tempus to grow its dataset, expand its experienced technical team, and establish a strong footprint in digital pathology with an industry leading technology portfolio. Founded in 2017, Paige has developed and deployed several AI applications, includ.
Tempus Announces the Acquisition of Paige
Positive
Zacks Investment Research
3 days ago
4 Medical Devices Behemoths to Buy Amid Extensive AI Applications
AI-driven innovations in medical devices are fueling growth for BSX, JNJ, GEHC and TEM.
4 Medical Devices Behemoths to Buy Amid Extensive AI Applications
Positive
MarketBeat
5 days ago
5 High Short-Interest Stocks to Buy Before November
This is a look at five stocks to consider buying before November. No, there isn't a major election cycle, but these high short-interest names have bullish market fundamentals and are expected to report their Q3 results in November.
5 High Short-Interest Stocks to Buy Before November
Positive
Zacks Investment Research
6 days ago
Strategic Partnerships Power Tempus AI's Healthcare Expansion
TEM deepens collaborations in oncology and neuroscience using its Lens and Next platforms to accelerate precision medicine.
Strategic Partnerships Power Tempus AI's Healthcare Expansion
Positive
Forbes
1 week ago
Tempus AI: TEM Stock To $130?
Tempus AI (NASDAQ: TEM) has already posted a strong 2x gain since its IPO, rising from $37 to $74. Although it trades at a lofty 14x trailing revenue multiple, the company's solid growth trajectory and expanding market opportunity indicate room for continued upside, as outlined below.
Tempus AI: TEM Stock To $130?
Neutral
GlobeNewsWire
1 week ago
TEMPUS ALERT: Bragar Eagel & Squire, P.C. is Investigating Tempus AI, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. Litigation Partner  Brandon Walker  Encourages Investors Who Suffered Losses In Tempus (TEM) To Contact Him Directly To Discuss Their Options
TEMPUS ALERT: Bragar Eagel & Squire, P.C. is Investigating Tempus AI, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Positive
Benzinga
1 week ago
Cathie Wood's Top 10 Stock Picks: Unpacking Ark Funds Innovation Picks For The Next Decade
Ark Invest CEO Cathie Wood is known for her stock picks over the last decade, handpicking many of the growth stocks that find their way into the company's ETFs.
Cathie Wood's Top 10 Stock Picks: Unpacking Ark Funds Innovation Picks For The Next Decade
Positive
MarketBeat
1 week ago
Tempus AI's Strong Q2 Fuels Growth Story—More Upside Ahead?
Over the past two years, one of the most interesting healthcare companies to go public is none other than Tempus AI NASDAQ: TEM. In a world where healthcare IPOs are typically dominated by biotech companies that generate little to no revenue, Tempus stands out.
Tempus AI's Strong Q2 Fuels Growth Story—More Upside Ahead?
Charts implemented using Lightweight Charts™